August 2020 in “Research Square (Research Square)”
The study investigated the effects of PRL-1-overexpressing placenta-derived mesenchymal stem cells (PD-MSCs PRL-1) on adipogenesis in orbital fibroblasts (OFs) from patients with Graves’ ophthalmopathy (GO). The research found that PD-MSCs PRL-1 significantly reduced lipid accumulation and decreased the expression of adipogenic markers in OFs compared to naïve cells. This effect was linked to the secretion of insulin-like growth factor-binding proteins (IGFBPs) by PD-MSCs PRL-1, which downregulated the PI3K/AKT/mTOR signaling pathway and upregulated phosphorylatedFAK through integrin interactions. These findings suggested that functionally enhanced PD-MSCs could offer a novel therapeutic approach for treating degenerative diseases like GO.